NEWAMSTERDAM PHARMA CO NV
NAMSNASDAQTrading Snapshot
- Day Range
- $20.55 – $21.72
- 52-Week Range
- $19.13 – $42.21
- Volume (shares)
- 1,029,056
- Avg Volume (shares)
- —
- Shares Outstanding
- 119.5M
- Next Earnings
- 2026-11-11
Fundamentals Snapshot
- Annual Revenue
- $23M
- Last Q Revenue
- $4M
- P/E Ratio
- —
- P/S Ratio
- 353.7x
- EPS (TTM)
- $-2.15
- Dividend Yield
- —
- Dilution (1yr)
- +17.9%
NEWAMSTERDAM PHARMA CO NV
NAMS
StockOtter · stockotter.spaceAbout NEWAMSTERDAM PHARMA CO NV
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
NewAmsterdam Pharma (NASDAQ:NAMS) Hits New 1-Year Low – Should You Sell?
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS - Get Free Report)'s stock price reached a new 52-week low during mid-day trading on Wednesday. The company traded as low as $20.04 and last traded at $20.19, with a volume
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, The Netherlands and MIAMI, Oct. 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral,
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer's Disease
- SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer's disease who do not have noticeable memory or functional symptoms- - The study will evaluate changes in blood-based
Menarini Group y NewAmsterdam Pharma reciben la aprobación de la Comisión Europea para Ubeslo® y Evlarco®
Menarini Group y NewAmsterdam Pharma reciben la aprobación de la Comisión Europea para Ubeslo (obicetrapib en monoterapia) y Evlarco (combinación a dosis
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
- First-in-Class approval supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM trials demonstrating significant LDL-C reductions with favorable tolerability profile-
Biogen (NASDAQ:BIIB) versus NewAmsterdam Pharma (NASDAQ:NAMS) Financial Analysis
NewAmsterdam Pharma (NASDAQ: NAMS - Get Free Report) and Biogen (NASDAQ: BIIB - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of th